Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 23, 2020
Onyx Scientific announced it is investing in a new facility at its UK site in order to prepare for the approval of a commercial API license.
read more
Optibrium Ltd and BioPharmics LLC, leading providers of software and computational solutions for drug discovery, announce their partnership. Industry-leading 3D ligand-based design approaches from BioPharmics will be available in Optibrium’s small ...
read more
Oragenics and Avid Bioservices announced the companies have entered into a process development and drug substance manufacturing agreement.
read more
Orchard Therapeutics and MolMed have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.
read more
Orientation Marketing, a pharmaceutical and life science marketing agency, opened a new office in Espoo, Finland to serve its growing client base in the Nordic and EU regions.
read more
OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization (CDMO), announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate ...
read more
Wednesday, April 02, 2014
OsoBio has appointed Catherine R. Buck director of manufacturing. In her capacity, Buck is responsible for ensuring that OsoBio’s operations comply with current Good Manufacturing Practices (cGMP) as they apply to the manufacturing of injectable ...
read more
OsoBio has named David M. Lee vice president of quality. Lee is responsible for overseeing all quality-related functions to ensure the company’s
continued compliance with Current Good Manufacturing Practices (cGMP), including quality
systems, ...
read more
OsoBio has named Lindsey Pruitt manager of new business development for its East Coast market.
read more
As part of OsoBio’s quality control department, the microbiology and chemistry laboratories that Larese now directs are responsible for environmental monitoring, analytical method development, and testing all incoming raw materials, components, and ...
read more
Friday, December 20, 2013
OsoBio has reaffirmed its long-standing partnership with the Drug, Chemical and Associated Technologies Association (DCAT) by accepting new volunteer leadership positions within the organization.
read more
Thursday, February 21, 2013
OsoBio President Milton Boyer will serve on a panel of experts examining shortages of injectable pharmaceuticals during DCAT Week.
read more
Ovid and Angelini Pharma have announced an agreement in which Angelini will be responsible to develop, manufacture and commercialize OV101 (gaboxadol).
read more
Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 for the potential treatment of Angelman syndrome.
read more
Oxford Biomedica announced the UK MHRA has issued a Certificate of GMP compliance for the fourth GMP manufacturing suite within the Group’s new Oxbox manufacturing facility.
read more